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Cost-effectiveness of single-photon emission computed tomography for diagnosis of 
coronary artery disease: a systematic review of the key drivers and quality of published 
literature 
Abstract 
Background: Single- photon-emission computed tomography (SPECT) being one of the most commonly 
used methods that significantly improved the detection of coronary artery disease. The objective of this 
study was to perform a systematic review of the cost-effectiveness of SPECT in diagnosis of coronary 
artery disease.  
Methods: Electronic databases including PubMed, Scopus and Web of Science were searched from 1997 
through 2017. The full economic evaluations of SPECT as the first and only test in diagnosis of coronary 
artery disease were included in this study. Non-English studies, conference abstracts and letters/editorials 
were excluded. The Consolidated Health Economic Evaluation Reporting Standards checklist was used to 
review the methodological quality of included studies.  
Results: Eight studies met the systematic review inclusion criteria. In general, the quality of the included 
studies was high. The abstract of studies had the least degree of compliance with the Consolidated Health 
Economic Evaluation Reporting Standards checklist. The majority of the papers used decision tree model 
and estimated cost from a payer’s perspective. This study revealed wide heterogeneity in the methodology 
particularly in setting, comparators, time horizon, and perspective.  
Conclusion: By conducting this systematic review on 8 valid studies, it was found that the cost-
effectiveness of an imaging test strongly depends on the pretest likelihood of disease. The included 
studies on cost-effectiveness provide conflicting evidence in support of the use of SPECT in diagnosis of 
coronary artery disease. This study showed that the cost-effectiveness of an imaging test varied between 
subgroups of patients.  
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1.Introduction: 
Non-communicable diseases accounted for about 60% of all deaths and 50% of the burden of 
disease in 2001 [1-3]. It is predicted that in 2020 both of death and global burden from Non-
communicable diseases will be about 70% in developing countries [3]. Coronary Artery Disease 
(CAD) is one of these non-communicable disorders that will increase dramatically throughout 
the world by 2020 [3]. Today, CAD is the main cause of death in developed countries [4]. The 
prevalence of CAD and coronary risk factors in developing countries is increasing [5]. 
According to the important role of CAD in morbidity and death, early recognition of CAD is an 
essential part of public health policies [6]. Coronary Angiography (CA) is an accepted reference 
standard for CAD diagnosis. However, CA is expensive, and major complications occur in 1% to 
2% of cases undergoing CA [7]. Thus, use of less invasive imaging tests is significant for 
decreasing or avoiding the Complications of CA [8]. Noninvasive tests with optimal sensitivity 
and specificity are developed to decide which patients should undergo coronary angiography [9]. 
In the past decades, various noninvasive tests for CAD diagnosis have become extensively 
available in clinical practice [10, 11]. Present guidelines advise the use of noninvasive imaging 
tests, such as Single-Photon-Emission Computed Tomography (SPECT), Positron Emission 
Tomographic (PET), Coronary Computed Tomographic Angiography (CCTA) and 
echocardiography, before coronary angiography in many people suspected of having CAD [9]. 
SPECT being one of the most commonly used methods that significantly improved the detection 
of CAD [12]. However, the effectiveness of SPECT for diagnosis of CAD is controversial [13]. 
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The recommendations of the present guidelines for the diagnosis of CAD are not the same, and 
in many conditions, the adoption of a diagnosis test depend on various factors such as clinical 
and economic issues [10, 14]. Cost-Effectiveness Analysis (CEA) is extensively used to support 
decision makers to choice the best alternatives within constrained healthcare system budgets [15, 
16]. It is defined as the comparative analysis of alternatives according to their costs and 
consequences [17]. In recent years, many of CEAs conducted on the different tests, including 
SPECT, for CAD diagnosis [18, 19]. Also, a systematic review has been conducted on 
previously published SPECT CEAs [20], but its focus has been on sensitivity and specificity of 
test, there has been no comprehensive assessment of the quality of these CEAs and the key 
drivers of cost effectiveness have not been identified. With the recent development of updated 
standards for economic evaluations of healthcare interventions, the main aim of this study is to 
perform a systematic review on the previously published studies to assess the cost-effectiveness 
of SPECT in diagnosis of CAD. Also, we evaluated the methodological quality of these CEAs 
using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist 
[21]. 
2.Methods: 
We performed a systematic review adhered to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement [22]. 
2.1.Search Strategy: 
A systematic review of the literature was performed to assess the cost-effectiveness of SPECT in 
diagnosis of CAD. Three electronic databases including Scopus, ISI Web of Science and 
PubMed for English literature published from October 1997 to October 2017 were searched. 
Search strategies for electronic databases were performed in accordance with Table 1. 
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Furthermore, references of included studies and relevant review studies manually examined for 
additional articles to be included. 
[Insert table 1] 
2.2.Study Selection: 
Records were entered into EndNote 8 (Thomson Reuters, New York, NY). Duplicate reports 
were deleted in the first step of selection of articles. In the second stage, two authors (JJN and 
AR) independently examined the titles and abstracts of all search results. Articles were excluded 
if the study was not an economic evaluation of diagnosis strategies for CAD, or if they were 
conference abstracts, letters/editorials or conference reports. In the next step, the same authors 
independently assessed the full-text articles. Studies were included if they met the following 
criteria: 
-Study design: Economic evaluation studies including cost effectiveness or cost utility 
-population Study: patients with suspected CAD 
-Outcome: Incremental Cost Effectiveness Ratio 
-Screening strategies: including SPECT as the first and only test 
-Languages: English  
Studies with following criteria were excluded: 
-Study design: conference abstracts, letters/editorials or conference reports, or not full economic 
evaluation of SPECT for CAD. 
-population Study: patients with underlying disease such as diabetes 
-Screening strategies: Several tests as a one strategy, stress SPECT, not include SPECT as the 
first and only test 
-Languages: Non-English  
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Any disagreements between authors were resolved through consensus and, in cases of persistent 
disagreement, a third author (MH) assessed the publications. A flow chart showing the selection 
procedure is demonstrated in Fig. 1. 
[Insert figure 1] 
2.3.Data Extraction: 
For each study included in the final review, data were extracted into a table. Data were extracted 
by JJN and confirmed by AR and MH. Again, any disagreements between authors were resolved 
through consensus and, in cases of persistent disagreement, a third author (VA) assessed the 
publications. The information obtained included authors, study year, country, comparators, 
decision model, cost effectiveness measure, study perspective, time horizon, sensitivity analysis, 
and study conclusions.  
2.4.Quality Assessment of economic evaluation studies: 
While there are various guidelines for economic evaluation studies [23-28], we used the 
CHEERS checklist because it consolidated and updated previous guidelines into a single Useful 
reporting standard [21, 29]. The CHEERS statement checklist developed by the ISPOR Health 
Economic Evaluation Publication Guidelines Task Force provides recommendations in a 
checklist to evaluate reporting in health economic evaluations. The aim of the CHEERS checklist 
is to provide recommendations to improve reporting of health economic evaluations. The 
CHEERS checklist contains 24 criteria assessing different aspects of quality and reporting 
standard of economic evaluations: background and objectives, target population and subgroups, 
setting and location, study perspective, comparators, time horizon, discount rate, choice of health 
outcomes, measurement of effectiveness, measurement and valuation of preference based 
outcomes, estimating resources and costs, choice of model, assumptions, analytical methods, 
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study parameters, incremental costs and outcomes, characterizing uncertainty, characterizing 
heterogeneity, study findings, limitations, generalizability, source of funding, and conflicts of 
interest. For each included study, each checklist item was rated as ‘‘0” or ‘‘1”. Furthermore, 
overall quality rating of eligible studies was scored on a four-point Likert scale in a descending 
order of ‘‘excellent”, ‘‘good”, moderate” or ‘‘low” quality when study fulfilled 100%, >75–
<100%, >50–75%, or 50% of the criteria, respectively [21, 29].  
3.Results: 
3.1.Study Selection: 
Figure 1 show the process of literature search. Systematic database search identified 402 
potentially relevant studies (PubMed: 96; Web of Science: 107; Scopus: 199). Additional records 
identified through other sources (n = 9). After the removal of duplicated (n = 107), 304 
publications remained. Of these, 255 were rejected when the title and the abstract were reviewed 
and found not to be relevant. The full text of the remaining 49 publications was examined. 41 
articles were excluded because they did not meet the eligibility criteria for the review (see Fig. 
1). Eight studies were selected for this systematic review [18, 19, 30-35]. 
3.2. Quality of economic evaluation studies: 
The results of the quality assessment of included CEAs according to the CHEERS checklist [21] 
are shown in Table 2. The quality assessment showed that the methodological quality of the 
included CEAs varied from 75% to 91.66%. Among the CHEERS checklist items, the abstract of 
articles (item 2) had the least degree of compliance with the CHEERS checklist (12.5%). 13 
items including title, target population, comparators, Choice of health outcomes, Measurement of 
effectiveness, estimating resources and costs, Currency price date  and conversion, Assumptions, 
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Analytic methods, Study parameters, Incremental costs and outcomes, Characterizing uncertainty 
and finding were the most compliance with the CHEERS checklist (100%). 
[Insert table 2] 
3.3. Summary characteristics: 
Some of the characteristics and key findings of eligible studies reported summarized in Table 3. 
Eight studies were selected for this systematic review [18, 19, 30-35]. The contribution of each 
of the continents of Asia [32, 33], Europe [18, 19] and the United States [31, 34] were two 
studies and two studies location were uncertain [30, 35]. Four articles provided both cost-
effectiveness and cost-utility analysis [19, 33-35], while three articles performed only a cost-
effectiveness [18, 31, 32] and one article conducted only a cost-utility analysis [30]. Majority of 
studies were conducted from the payer perspective [19, 32, 34, 35], two studies used a societal 
perspective [18, 30], one study conducted from health care system perspective [33] and one 
study perspective was uncertain [31]. Different durations of time horizon were used. Only two 
studies used a lifetime horizon [34, 35]. Three article used a discount rate that all of them applied 
rates of 3% [30, 32, 35]. 
[Insert table 3] 
4. Discussion: 
In this study, we systematically reviewed the economic evaluations of SPECT in diagnosis of 
CAD. Although, we found another review on SPECT CEAs [20], but the current study 
systematically reviewed the key drivers of cost effectiveness of SPECT in diagnosis of CAD. 
Also, we evaluated the methodological quality of these CEAs using the CHEERS checklist. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
These items are not identified in the previous review. A comprehensive electronic and manual 
search found 8 economic evaluations of SPECT in diagnosis of CAD. 
4.1. Quality assessment: 
Included papers were assessed with CHEERS checklist. CHEERS Checklist reviewed the very 
detailed information of an economic evaluation study. In recent years, significant improvements 
have been made in the quality of economic evaluation reports. Although, none of the 8 articles 
included in this study could earn 100% CHEERS Checklist scores, but the quality of included 
studies was appropriate. Six studies were of good quality based on the CHEERS checklist [19, 
30, 32-35], two studies were of moderate quality [18, 31], and none was of excellent and low. All 
studies completely met criteria for reporting title, target population, comparators, Choice of 
health outcomes, Measurement of effectiveness, estimating resources and costs, Currency price 
date  and conversion, Assumptions, Analytic methods, Study parameters, Incremental costs and 
outcomes, Characterizing uncertainty and finding. Only one study met criteria for abstract [30], 
which could be due to limitations of journals or publications for abstract. CHEERS checklist 
recommended that introduction for an economic evaluation report must provide an explicit report 
of the broader context for the study [21]. Only three studies met this criteria [32, 33, 35]. In two 
studies Setting and location did not clearly state [30, 35]. Also, one study did not describe the 
perspective of study [31]. Five studies did not report the discount rate [18, 19, 31, 33]. One of 
these studies [33] used a short horizon (1 year) that did not require the use of a discount rate. 
However, CHEERS checklist recommended that in studies with short horizons, discount rate 
must described as 0% [21]. Two studies did not report the time horizon and did not used the 
preference-based outcomes [18, 32]. The CHEERS checklist recommended that reasons for 
choosing a model for study must be described and the model structure should also be represented 
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using a figure [21]. Two studies did not met this criteria [18, 31]. CHEERS checklist for 
characterizing heterogeneity recommended that cost-effectiveness results explained according to 
variations between subgroups of patients with different baseline characteristics or other variables 
[21]. This item was met by six studies [18, 19, 30, 32, 33, 35]. These studies had a subgroup 
analysis according to Pretest Likelihood of Disease (PLD). One study also explained cost 
effectiveness results based on age and sex [30]. Three studies did not describe any potential for 
conflicts of interest of study contributors [30, 32, 35]. One study did not clearly state the funding 
sources [32]. 
4.2. Cost-Effectiveness: 
By conducting this systematic review on 8 valid studies, it was found that the cost-effectiveness 
of an imaging test strongly depends on the PLD. 
Cost-effectiveness considerations suggest that echocardiography, SPECT, and immediate 
angiography are the most appropriate diagnostic tests for patients at intermediate pretest risk for 
having coronary disease. At a 25% prevalence of disease, echocardiography seems to be the most 
attractive test under most circumstances; SPECT would be chosen over echocardiography only if 
a cost-effectiveness ratio of $110 000 is considered acceptable, and immediate angiography 
would be chosen over SPECT only at a cost-effectiveness ratio of $355 000. Thus, 
echocardiography remains a cost-effective strategy at a wide range of prevalence of disease, 
whereas immediate angiography is a cost-effective choice when the pretest probability of disease 
is high [30]. The results of another study indicated that imaging modalities that include cardiac 
CCTA are the most cost-effective methods in symptomatic patients with suspected obstructive 
CAD and a PLD of ≤50%. In high-risk patients (PLD > 50%), immediate Invasive coronary 
angiography (CATH) appears to be the most cost-effective strategy. This study showed that 
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ischemia imaging techniques (SPECT and Stress Echo) are more expensive and less effective 
compared with other diagnostic strategies for all assessed PLDs [18]. In another study, The cost-
effectiveness acceptability curves from the probabilistic sensitivity analysis showed that at 30% 
and 50% CAD prevalence or the coronary CT angiography–first or coronary CT angiography–
only strategy was the most cost-effective up to the threshold level of $50 000 per QALY. At a 
higher CAD prevalence of 80%, however, the invasive coronary angiography approach was the 
most cost-effective strategy, with an ICER of $7994.36 relative to the coronary CT angiography–
only approach. Coronary CT angiography–first and coronary CT angiography–only strategies 
remained dominant up to a baseline coronary CT angiography test cost of $1100 and 80% CAD 
prevalence [35]. The results of some included studies showed that the SPECT is a dominated 
strategy in CAD diagnosis. One study compared cost-effectiveness of Dual-Energy Computed 
Tomography (DECT) versus of SPECT for diagnosis of CAD. This study showed that compared 
to SPECT, DECT was dominant strategy [34]. Another study that conducted cost effectiveness 
of MRI and SPECT in CAD found that for patients with any pre-test likelihood of CAD, p-MRI 
was a cost-effective strategy in the comparison of SPECT [32]. In comparison of SPECT and 
cardiovascular magnetic resonance (CMR), showed that CMR has relatively better cost-
effectiveness and utility across all prevalence levels and the full range of sensitivity analyses 
[19]. However, SPECT was dominant versus Positron-Emission Tomography (PET). Hlatky et al 
compared the cost-effectiveness of coronary computed tomography angiography (CTA), PET 
and SPECT in diagnosis of CAD. They resulted that SPECT has better cost-effectiveness 
compared with PET, whereas CTA was associated with higher costs and no significant difference 
in mortality compared with SPECT [31]. Another study was conducted a Cost-effectiveness of 
SPECT against CCTA using test accuracy and quality-adjusted life year (QALY). In the model 
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using diagnostic accuracy, CCTA was more effective and less expensive than SPECT ($725.38 
for CCTA vs. $661.46 for SPECT). In the model using QALY, CCTA was generally more 
effective in terms of life quality (0.00221 QALY) and cost ($513) than SPECT. However, cost 
utility varied among subgroups, with SPECT outperforming CCTA in patients with a pretest 
probability of 30% to 60% (0.01890 QALY; $113) [33]. 
There are several limitations in this systematic review including the exclusion of unpublished 
manuscripts and abstracts from conference proceedings. 
5. Conclusion: 
This study provides a valuable information on the key drivers and trends in cost effectiveness of 
SPECT in CAD diagnosis for decision makers and stakeholders. Due to heterogeneity in the 
methodology (comparators, time horizon, and perspective) and data sources (effectiveness and 
costing data) of CEAs, no synthesis of the data was possible. Instead, we summarized key drivers 
and major finding of CEAs. The included studies on cost-effectiveness provide conflicting 
evidence in support of the use of SPECT in diagnosis of CAD. This study showed that the cost-
effectiveness of an imaging test varied between subgroups of patients such as PLD, sex and age. 
CHEERS checklist recommended that cost-effectiveness results explained adhere to variations 
between subgroups of patients with different baseline characteristics or other variables. While 
the quality of the included CEAs was generally high, some of the CEAs could not provide all the 
detailed evidence required by the CHEERS checklist. If allowed by journal or publication 
restrictions, next CEAs should adhere to standard reporting guidelines, such as CHEERS, so that 
readers can assess and compare the quality of study results. 
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Table 1: Search strategies for PubMed, Scopus and ISI 
Database Search Strategy 
PubMed (“Cost-Benefit Analysis” [MeSH] OR “Economic evaluation” [tiab] OR “Cost 
effectiveness” [tiab] OR “Cost-benefit” [tiab] OR “Cost-utility” [tiab]) AND 
(“Tomography, Emission-Computed, Single-Photon” [MeSH] OR “single Photon 
Emission Computed Tomography” [tiab] OR spect[tiab]) AND (“coronary artery 
disease” [MeSH] OR “coronary artery disease” [tiab]) 
Scopus TITLE-ABS-KEY(“Cost-Benefit Analysis” OR “Economic evaluation” OR “Cost 
effectiveness” OR “Cost-benefit” OR “Cost-utility”) AND TITLE-ABS-
KEY(“Tomography, Emission-Computed, Single-Photon” OR “single Photon 
Emission Computed Tomography” OR spect) AND TITLE-ABS-KEY(“coronary 
artery disease”) 
ISI 1. “Cost-Benefit Analysis” OR “Economic evaluation” OR “Cost effectiveness” 
OR “Cost-benefit” OR “Cost-utility” 
2. “Tomography, Emission-Computed, Single-Photon” OR “single Photon 
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Emission Computed Tomography” OR spect 
3. “coronary artery disease” 
4. 1 And 2 AND 3 
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Table 2: Quality of the included studies using CHEERS checklist  
Item 
no. 
Section/item Ferreira 
[18] 
Boldt 
[19] 
Lee 
[33] 
Hlatky 
[31] 
Meyer 
[34] 
Garber 
[30] 
Min 
[35] 
Iwata 
[32] 
Overall 
1 Title 1 1 1 1 1 1 1 1 %100 
2 Abstract 0 0 0 0 0 1 0 0 %12.5 
3 Background and objectives 0 0 1 0 0 0 1 1 %37.5 
4 Target population and subgroups 1 1 1 1 1 1 1 1 %100 
5 Setting and location 1 1 1 1 1 0 0 1 %75 
6 Study perspective 1 1 1 0 1 1 1 1 %87.5 
7 Comparators 1 1 1 1 1 1 1 1 %100 
8 Time horizon 0 1 1 1 1 1 1 0 %75 
9 Discount rate 0 0 0 0 0 1 1 1 %37.5 
10 Choice of health outcomes 1 1 1 1 1 1 1 1 %100 
11 Measurement of effectiveness 1 1 1 1 1 1 1 1 %100 
12 Measurement and valuation of preference-
based outcomes 
0 1 1 1 1 1 1 0 %75 
13 Estimating resources and costs 1 1 1 1 1 1 1 1 %100 
14 Currency, price date, and conversion 1 1 1 1 1 1 1 1 %100 
15 Choice of model 0 1 1 0 1 1 1 1 %75 
16 Assumptions 1 1 1 1 1 1 1 1 %100 
17 Analytic methods 1 1 1 1 1 1 1 1 %100 
18 Study parameters 1 1 1 1 1 1 1 1 %100 
19 Incremental costs and outcomes 1 1 1 1 1 1 1 1 %100 
20 Characterizing uncertainty 1 1 1 1 1 1 1 1 %100 
21 Characterizing heterogeneity 1 1 1 0 0 1 1 1 %75 
22 Study findings, limitations, generalizability, 
and current knowledge 
1 1 1 1 1 1 1 1 %100 
23 Source of funding 1 1 1 1 1 1 1 0 %87.5 
24 Conflicts of interest 1 1 1 1 1 0 0 0 %62.5 
 Overall quality  %75 %87.5 %91.66 %75 %83.33 %87.5 %87.
5 
%79.16  
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Table 3: key drivers and major finding of the included studies 
Author year Country Imaging 
modalities 
Model Cost-
Effectiveness 
Measure 
Study 
perspective 
Time 
horizon 
Major findings 
António 
Miguel 
Ferreira 
[18] 
2013 Portugal ET-MPS  
ET-CCTA  
SPECT 
StressEcho  
CCTA  
CACS-CCTA  
CATH 
decision-
making tree 
 
Bayesian 
inference 
cost per 
correct 
diagnosis 
society’s 
perspective 
 Diagnostic algorithms that include 
cardiac computed tomography 
angiography are the most cost-
effective in symptomatic patients with 
suspected stable coronary artery 
disease and a pretest likelihood of 
disease of ≤50%. 
In high‑risk patients (pretest 
likelihood of disease ≥ 60%), up-front 
invasive coronary angiography 
appears to be the most cost-effective 
strategy. In all pretest likelihoods of 
disease, strategies based on ischemia 
appear to be more expensive and less 
effective compared with those based 
on anatomical tests. 
Julia 
Boldt 
[19] 
2013 Germany CMR 
SPECT 
invasive 
coronary 
angiography 
Bayes’ 
theorem 
cost per 
accurate 
diagnosis of 
CAD 
 
cost per 
quality-
adjusted life-
years gained 
(∆QALY) 
health care 
payer’s 
perspective 
10 y In patients with low to intermediate 
pretest probabilities, CMR is more 
cost-effective for the detection of 
CAD than SPECT. The superior 
diagnostic accuracy of CMR also leads 
to an improved clinical utility as 
indicated by lower costs per number of 
QALYs gained. Above a threshold 
value of CAD prevalence of 0.60, 
proceeding directly to invasive 
angiography was found to be the most 
cost-effective diagnostic strategy. 
Seung-
Pyo Lee 
2015 Korea CCTA 
SPECT 
decision tree cost per 
accurate 
health 
care system 
1 y In the model using diagnostic 
accuracy, CCTA was more effective 
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[33] CAG diagnosis of 
CAD 
 
cost per 
quality-
adjusted life-
years gained 
(∆QALY) 
perspective and less expensive than SPECT 
($725.38 for CCTA vs $661.46 for 
SPECT). In the model using QALY, 
CCTA was generally more effective in 
terms of life quality (0.00221 QALY) 
and cost ($513) than SPECT. 
However, cost utility varied among 
subgroups, with SPECT 
outperforming CCTA in patients with 
a pretest probability of 30% to 60% 
(0.01890 QALY; $113). 
Mark A. 
Hlatky 
[31] 
2014 United 
States & 
Canada 
CTA 
SPECT 
PET 
multivariable 
analysis 
Cost per life-
year added 
 
N/A 2 y SPECT was economically attractive 
compared with PET, whereas CTA 
was associated with higher costs and 
no significant difference in mortality 
compared with SPECT. 
Mathias 
Meyer 
[34] 
2012 United 
States 
DECT 
SPECT 
Monte Carlo 
simulation 
model 
Cost per 
correct 
diagnose 
 
cost per 
QALY 
payer 
perspective 
Lifetim
e 
SPECT was significant less effective if 
compared to DECT with an ICER of 
$3557 per QALY (p=0.0004) and 
$3625 per correct diagnose 
(p=0.0001). 
Alan M. 
Garber 
[30] 
1999 - Angiography 
PET 
SPECT 
Echo 
Planar 
thallium 
imaging 
Exercise 
electrocardio
graphy 
decision tree 
 
Markov 
Model 
costs per 
QALY 
 
 
Societal 
perspective 
30 y Cost-effectiveness considerations 
suggest that echocardiography, 
SPECT, and immediate angiography 
are the most appropriate diagnostic 
tests for patients at intermediate 
pretest risk for having coronary 
disease. 
James 
K. Min 
[35] 
2010 Payers 
perspecti
ve 
CCTA 
SPECT 
Markov 
Model 
cost per 
correct 
diagnosis 
 
payer 
perspective 
Lifetim
e 
With a $20 000 threshold level for cost 
per correct diagnosis and $50 000 per 
QALY, a coronary CT angiography–
only approach is the most cost-
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costs per 
QALY 
effective diagnostic strategy for 
evaluation of patients who have stable 
chest pain without known CAD with 
intermediate CAD prevalence. 
Kunihir
o Iwata 
[32] 
2012 Japan MRI 
SPECT 
Decision tree 
model 
Cost per 
correct 
diagnosis 
payer’s 
perspective 
 For outpatients with chest pain, p-MRI 
had good clinical effectiveness and 
cost-effectiveness compared with 
SPECT. In the management of patients 
with suspected CAD, p-MRI is as 
useful as SPECT. 
ET-MPS: Ergometric test followed by myocardial perfusion scintigraphy 
ET-CCTA: Ergometric test followed by cardiac computed tomography angiography 
CACS-CCTA: calcium scoring followed by cardiac computed tomography angiography 
CCTA: cardiac computed tomography angiography 
SPECT: single photon emission computed tomography 
CATH: invasive coronary angiography 
CMR: cardiovascular magnetic resonance 
CAG: Coronary angiography 
CTA: coronary computed tomography angiography 
PET: positron-emission tomography 
DECT: dual-energy computed tomography 
MRI: magnetic resonance imaging 
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Figure 1: PRISMA flow diagram of the selection process used to identify studies for inclusion in this 
review.  
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